GNCA stock down 97% to $0.0001 on NASDAQ: Key metrics and what to watch next

GNCA stock closed the market on 17 Feb 2026 at $0.0001, down -97.44% on the day on the NASDAQ in the United States. Trading volume for the session was 30,268 shares versus a 50-day average of 80,568, after the stock opened at $0.0007 and hit an intraday high and low of $0.0001. The plunge follows a long decline from a 52-week high of $1.45, leaving liquidity thin and the float effectively near zero. Investors should watch cash per share, enterprise value metrics, and any Chapter 11 follow-up that could drive further GNCA stock moves.

GNCA stock: Price action, volume and session summary

GNCA stock finished at $0.0001 on NASDAQ on 17 Feb 2026, a decline of -97.44% from the prior close of $0.0039. Volume was 30,268 versus an average volume of 80,568, giving a relative volume of 0.38 and signalling low liquidity. The 50-day average price is $0.00 (reported $0.004724) and the 200-day average is $0.11 (reported $0.114619), highlighting a sustained downtrend and extreme dispersion from longer-run averages.

GNCA stock: Drivers of the decline and recent news context

The rapid fall tracks the company’s Chapter 11 filing in July 2022 and subsequent delisting risks that left shares thinly traded. Genocea Biosciences, Inc. remains in the Biotechnology industry within Healthcare, and uncertainty around clinical programs such as GEN-009 and GEN-011 has weighed on sentiment. Market commentary on competitors and peer moves can cross-impact GNCA; see competitor lists and biotech coverage on MarketBeat for context MarketBeat competitor list and broader biotech headlines MarketBeat biotech coverage.

GNCA stock: Financial health and key metrics

Genocea reports cash per share $0.54 and book value per share $0.39, while operating cash flow per share is -0.66 and free cash flow per share is -0.71, indicating negative cash generation. The current ratio is 2.24 and debt to equity is 0.41, suggesting short-term liquidity remains positive despite operational losses. Enterprise value is reported as -26,015,000.00, with revenue per share 0.02 and net income per share -0.22, underscoring a biotech balance sheet rather than profitable operations.

GNCA stock: Technical and trading considerations

Technically, GNCA stock sits at its 52-week low $0.0001, far below the 50-day $0.004724 and 200-day $0.114619 averages. Price volatility measures show massive historical drawdowns: 3-month change -98.31% and 1-year change -99.99%, which increases execution risk for larger orders. With market cap effectively $0.00 in reported feeds and shares outstanding not clearly quoted, traders face severe slippage and potential quote inconsistency on NASDAQ.

GNCA stock: Meyka AI grade, analyst view and risks

Meyka AI rates GNCA with a score out of 100: 62.42 / B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, industry comparison, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. Key risks include Chapter 11 outcomes, thin liquidity, clinical trial uncertainty, and potential delisting; opportunities are limited and hinge on restructuring outcomes and asset recoveries. The grade is informational and not personalized investment advice.

Final Thoughts

Key takeaways for GNCA stock: the share price closed at $0.0001 on NASDAQ on 17 Feb 2026, reflecting a -97.44% one-day move and continued collapse from a 52-week high of $1.45. Financially, Genocea shows cash per share $0.54, book value per share $0.39, and negative operating cash flow per share -0.66, which paints a picture of a small biotech with remaining cash but no operational profitability. Meyka AI’s forecast model projects a near-term nominal value of $0.00, compared with the current price of $0.0001, implying an effectively -100.00% downside in that baseline model; forecasts are model-based projections and not guarantees. Given the thin liquidity, enterprise value distortion, and bankruptcy-related history, our analysis frames GNCA stock as high risk with limited upside absent a clear restructuring win or asset sale. For live quotes and tracking, see the Meyka GNCA page and follow regulatory filings closely: Meyka GNCA page. Meyka AI provides this data-driven market analysis to surface risks, metrics, and potential scenarios for investors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.